TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04191577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVN424 Low Dose
Description: CVN424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVN424 High Dose
Description: CVN424

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00790738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine (T3)
Description: liothyronine (T3) up to 50 micrograms a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04757909

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Monthly Haemoglobinometry
Description: Monthly measurement of capillary hemoglobin with non-invasive techniques in primary health care.~Inclusion in a transfusion circuit with referral to a hospital day hospital if necessary.
Study: NCT00668304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Moxifloxacin 400 mg once orally daily
Study: NCT05181020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal Voice Exposure
Description: Main objective of this study is to determine if it is possible to expose preterm infant in a systematic manner to mother's voices before their feeds and to determine if this exposure results in an increase in their oral intake.
Study: NCT03365479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Single administration of inhaled iloprost 2.5 μg delivered via Breelib nebulizer
Study: NCT04143672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic digital pressure algometer
Description: Evaluation of pain threshold using an algometer is conducted one day before surgery.~The pressure of the plunger of algometer is applied vertically to the patient's right thenar muscle belly at a speed of 10 N/sec by the tester. Then the tester removes the algometer when the patients start to feel pain and record the pressure recorded on the algometer.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pain sensitivity questionnaire
Description: Evaluation of pain threshold using the Korean-version pain sensitivity questionnaire is conducted one day before surgery.
Study: NCT01485926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Carboplatin and Trastuzumab
Description: 6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab 8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Carboplatin, Trastuzumab and Lapatinib
Description: 6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab (8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter.) + Lapatinib (1000mg daily) until 1 week prior to surgery. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
Study: NCT04397718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix is an FDA-approved drug for prostate cancer

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 09% Saline
Study: NCT01952730

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX
Study: NCT04078672

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NOTAL-OCT V3.0
Description: AMD and DR patients
Study: NCT01029886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once weekly
Description: subcutaneous injection, 2mg, once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: subcutaneous injection, forced titration to 1.8mg, once daily
Study: NCT01928043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Study: NCT03071705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg PO BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TKI
Description: standard dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI
Description: standard dose
Study: NCT03938441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: The version of 5:2 intermittent fasting to be applied in this study will be somewhat less intensive than implemented then what has been proposed in some recent, similar studies.~On fasting days, instead of limiting the subject to a specific calorie count, the subject will be instead instructed to skip either the first or last meal of the day in order to complete a 12 to 16 hour fast, during which time they are allowed drink water or any non-caloric beverage of their choice, but not consume any calories.~Furthermore, the patient will be instructed for their remaining 2 meals to consume no more than they would on a normal, non-fasting day.
Study: NCT01647659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib tablet
Description: 2 mg, orally, on Day 1 of the dosing period
Study: NCT00489281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Given at 500 mg PO twice daily from Day -6 to Day +365.
Study: NCT01647659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib pediatric formulation
Description: 2 mg, orally, on Day 1 of the dosing period
Study: NCT05299814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parenting Intervention
Description: 8 session evidence based parenting intervention
Study: NCT01156597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: 30 mg daily for three weeks increase to 45 mg daily for 21 more weeks
Study: NCT02649543

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Closure
Description: A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. Subcutaneous tissue was approximated with Polyglycolic Acid 3-0, and the skin is sutured using Polypropylene 2-0.
Study: NCT00489281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Given at 500 mg PO twice daily from Day -6 to Day +365.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin
Description: Test dose of 0.5 mg/kg IV given on Day -9, then 2 mg/kg/day IV on Day -8 and -7.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin
Description: Test dose of 0.5 mg/kg IV given on Day -9, then 2 mg/kg/day IV on Day -8 and -7.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation - 400
Description: 400 centigray (cGy) in one fraction on Day -1.
Study: NCT00669981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral couples therapy for post-traumatic stress disorder (CBCT for PTSD)
Description: CBCT for PTSD is a 15-session manualized couples therapy that aims to both decrease individual PTSD symptoms and improve dyadic functioning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral couples therapy for post-traumatic stress disorder (CBCT for PTSD)
Description: CBCT for PTSD is a 15-session manualized couples therapy that aims to both decrease individual PTSD symptoms and improve dyadic functioning.
Study: NCT04119999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device
Description: Mandibular advancement device (MAD) has been a novel method in the management of snoring and OSA. For mild to moderate sleep apnea, MADs have been a boon. A guideline published by American Academy of Sleep Medicine stated that MAD was indicated as first-line therapy for mild OSA and a second-line therapy for moderate to severe OSA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure
Description: Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in people with OSA
Study: NCT04070287

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: SMART Pack
Description: The SMART pack is a re-branded and repackaged box for HIV self-testing kits. The intervention aims to promote distribution of HIVST kits through in institutions, vocational centers, and social media platforms. The intervention would also include a referral systems, where participants provided with the HIV self-testing kits are provided with information with youth-friendly health facilities for uptake of testing for sexually transmitted infections. The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the SMART pack and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Yaba local government area in Lagos state.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Luv Box
Description: The Luv box is packaged in two colors: blue and pink. The LUVBox would be made available in supermarkets, on-line stores, mini-marts, pharmacies, neighborhood stores and markets, for easy accessibility in hard to reach areas. The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the Luv Box and the location where the pack can be obtained for individuals who are interested.For this pilot study, the intervention will be implemented in Yaba in Lagos state.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Bili Vibes
Description: The HIV self-testing kits will be available for interested individuals at the community youth events. These events and information the HIV self-testing kits will be on flyers that would be promoted at community centers and schools. For this pilot study, the intervention will be implemented in Ngenevu/Bunker communities in Enugu state.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: BeterDoc
Description: The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the BeterDoc Safety Kits and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Ibadan, Dugbe and Agbowo in Oyo state.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: IUNGO
Description: The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the HIV self-testing kits and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Akure South, Orita-Obele, Ipinsa, Ilara Mokin and Ijare in Ondo state.
Study: NCT01394848

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endothelial cell capture stent with 1 month clopidogrel
Description: 75mg PO clopidogrel per day for 1 months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus eluting stent with 12 month clopidogrel
Description: 75mg PO clopidogrel per day for over 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20mg loading
Description: Atorvastatin 20mg loading before index percutaneous coronary intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80mg loading
Description: Atorvastatin 80mg loading before index percutaneous coronary intervention
Study: NCT02495181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Aflibercept
Study: NCT01100125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: sitagliptin 100mg once daily, orally, for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin dose increase
Description: insulin dose increase
Study: NCT05729672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Received the Nightingale in Gen-sEx course
Description: The experimental group (n=75) will participate in the SPOC- based education program, consisting of five online teaching and learning modules over the span of 3 months and two hours of offline classroom.
Study: NCT01041417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-Macrophage Stimulating Factor (GM-CSF)
Description: 500 micrograms of GM-CSF

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection
Study: NCT03365895

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging
Description: Undergo non-enhanced MRI using MRN and DTI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo non-enhanced MRI using MRN and DTI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03226899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lesinurad
Description: 200 mg oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XOI
Description: All participants must be on a stable, medically appropriate dose of XOI as their sole urate-lowering therapy (ULT) indicated for the treatment of gout for at least 4 weeks prior to Screening and throughout the Screening Period. This stable dose of XOI will be maintained throughout the study period.
Study: NCT02495181

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intravitreal Aflibercept
Study: NCT04294342

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Participants in 10 week Judo Inspired Exercise program
Description: The intervention included 10 sessions, using a 10-week (45-50 minutes /week) pre-established program called Judo4Balance, a structured exercise program. Each session consisting of warm-up, balance, strength, power and break fall exercises. There is clear a progression within the 10 week program in three main blocks. Block 1: learning the exercises and principle movements, Block 2 more resistance and advance falling techniques, Block 3 Power training and falling strategies from stand up positions.
Study: NCT02317679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Patients with PWS resistant to PDL treatment will be included. The treatment by Bosentan (twice daily :2 mg/kg and maximum 62,5 mg) will be given 1 day before the PDL irradiation (maximum area treated 100 cm2) and continued for 14 days. The clinical improvement of the lesions will be evaluated by comparing standardized pictures, 14 days after the end of the treatment by Bosentan which corresponds to 1 month after the laser PDL irradiation. The evaluation will be realized by 2 independent physicians blinded to the area treated or not. Hemoglobin and SGOT/SGPT will be controlled before and after the treatment by Bosentan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL)
Description: A test area of the PWS will be treated by pulsed dye laser (PDL) (λ= 595 nm, 7 mm spot diameter, τp= 1.5 ms, same energy density used at the last session for each subject).
Study: NCT03226899

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XOI
Description: All participants must be on a stable, medically appropriate dose of XOI as their sole urate-lowering therapy (ULT) indicated for the treatment of gout for at least 4 weeks prior to Screening and throughout the Screening Period. This stable dose of XOI will be maintained throughout the study period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colchicine
Description: Gout flare prophylaxis: commercially available colchicine is provided through the Month 6 study visit. Actual colchicine dose (0.5 or 0.6 mg qd) and frequency were adjusted based on the local label, subject medical history, and clinical judgement.
Study: NCT03639974

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEP in a blow-bottle device
Description: A 500-milliliter enteral nutrition vial will be used, which will contain a hole in the side, where two silicone tubes of 20 centimeters long will be inserted together with tape on the bottleneck of the vial. To perform the exercise, the vial will be filled with water leaving a water column of 10 cm high. Deep inspirations will be requested at a volume greater than the tidal volume and less than the total lung capacity that can be performed via nasal or oral, then with the mouth connected to the extensors, the patient will exhale slowly, avoiding to totally empty the lungs. The protocol will be executed twice a day, three sets of ten repetitions. The group will receive the conventional physiotherapy of the cardiac intensive care unit of the HCPA.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EPAP
Description: The Vital Signs ® EPAP kit will be used. Exercises will be performed in the bed, and as soon as the patient is released by the medical team to leave the bed, they can be performed in the sitting position or in orthostasis. For performing the exercise, the EPAP mask will be connected to the face of the patient. The expiratory pressure will be adjusted to 10cmH2O. Deep inspirations will be requested at a volume greater than the tidal volume and below the total lung capacity, then the patient will exhale slowly. The protocol will be executed twice a day, three sets of ten repetitions. The group will receive the conventional physiotherapy of the cardiac intensive care unit of the HCPA, as described in the conventional physiotherapy group.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: conventional physiotherapy
Description: Conventional physical therapy consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resisted lower limb exercises; stretching, cough and walking guidelines. Initially the exercises will be performed in the bed, as soon as this is withdrawn and the patient is released by the medical team to leave the bed, the progression of the exercises to be performed in the sitting position, orthostasis, and ambulation is performed, this usually occurs on the 2nd postoperative day, after the removal of the mediastinal drain . Under supervision of the physiotherapist, the protocol will be performed twice daily, two sets of ten repetitions.
Study: NCT01835704

Intervention type: OTHER
Intervention: Radio-frequency dennervation of facet joint

Intervention type: OTHER
Intervention: Diagnostic nerve-blocks performed under direct x-ray vision
Study: NCT01124695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen
Description: PO
Study: NCT03333499

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YanXinShi placebo pills
Description: participants will take matched 1800 mg YXS placebo pills TID in addition to the optimal combination drug treatment of heart failure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YanXinShi pills
Description: participants will take 1800 mg YXS pills TID in addition to the optimal combination drug treatment of heart failure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimetazidine pills
Description: participants will take 20mg Trimetazidine pills TID in addition to the optimal combination drug treatment of heart failure

Intervention type: DRUG
Group type: OTHER
Intervention: YanXinShi and Trimetazidine pills
Description: participants will take 1800 mg YXS and 20 mg Trimetazidine pills TID in addition to the optimal combination drug treatment of heart failure
Study: NCT01089621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 30 mg to 120 mg administered orally, daily for 12 weeks
Study: NCT00614926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Dose schedule: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day as clinically indicated, in the absence of dose-limiting side effects. Dose is daily, in A.M., for 4 weeks.
Study: NCT03226899

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: colchicine
Description: Gout flare prophylaxis: commercially available colchicine is provided through the Month 6 study visit. Actual colchicine dose (0.5 or 0.6 mg qd) and frequency were adjusted based on the local label, subject medical history, and clinical judgement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: Gout flare prophylaxis: Participants unable to take colchicine are permitted to take a short course of low-dose oral corticosteroids up to the Month 3 study visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: corticosteroids
Description: Gout flare prophylaxis: Participants unable to take colchicine are permitted to take a short course of low-dose oral corticosteroids up to the Month 3 study visit
Study: NCT03236909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MED-EL SYNCHRONY/SYNCHRONY PIN Cochlear Implant System
Description: Subjects will be implanted with the MED-EL SYNCHRONY/SYNCHRONY PIN Cochlear Implant System with +FLEX28 or +FLEXSOFT electrode arrays. Subjects will be fit with the SONNETEAS (ear-level) and/or RONDO (single-unit) external audio processors.
Study: NCT02829372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD3/HER2 bispecific monoclonal antibody
Description: Increasing doses, IV on day 1 and 15 of each 28 day cycle
Study: NCT02182518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinastine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinastine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo during run-in period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo during run-in period
Study: NCT02605902

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: (i)Comprehensive Behavioral Intervention for Tics

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: (i)Comprehensive Behavioral Intervention for Tics

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: internet-delivered psychoeducation and relaxation training
Study: NCT06193850

Intervention type: OTHER
Intervention: Observation during time
Description: Evaluation through clinical investigation and questionnaires useful for evaluating the patient's psycho-physical conditions